Risk Adjusted Net Present Value: What is the current valuation of Iovance Biotherapeutics’s Lifileucel

Lifileucel (LN-145) i

Newron Pharmaceuticals reports on its 2024 Investor Day in New York City – Biotech Investments

EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): Miscellaneous Newron Pharmaceuticals reports on its 2024 Investor Day in New York City 25.06.2024 / 17:45 CET/CEST The

June 26, 2024

Kymera’s protein degrader starts Phase II trial in atopic dermatitis

Share this article The Phase II trials for KT-474 in AD and HS are expected to be completed in Q1 2025. Image Credit: IrinaFoto /

December 8, 2023

New insights into how and when bipedal locomotion evolved in human ancestors

One of the most fascinating periods in the evolution of the human lineage is the appearance of the first ancestors capable of bipedalism.

November 28, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.